Abstract: Cooperation between endothelial cells and bone in bone remodelling is well established. In contrast, bone microvasculature supporting the growth of primary tumors and metastasis is poorly understood. Several antiangiogenic agents have recently been undergoing trials, although an extensive body of clinical data and experimental research have proved that angiogenic pathways differ in each tumor type and stage. Here, for the first time, we characterize at the molecular and functional level tumor endothelial cells from human bone sarcomas at different stages of disease and with different histotypes. We selected a CD31+ subpopulation from biopsies that displayed the capability to grow as adherent cell lines without vascular endothelial growth factor (VEGF). Our findings show the existence in human primary bone sarcomas of highly proliferative endothelial cells expressing CD31, CD44, CD105, CD146 and CD90 markers. These cells are committed to develop capillary-like structures and colony formation units, and to produce nitric oxide. We believe that a better understanding of tumor vasculature could be a valid tool for the design of an efficacious antiangiogenic therapy as adjuvant treatment of sarcomas.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Infante, T.; Cesario, E.; Gallo, M.; Fazioli, F.; De Chiara, A.; Tutucci, C.; Apice, G.; de Nigris, F. Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells. Cancers 2013, 5, 404-417.
Infante T, Cesario E, Gallo M, Fazioli F, De Chiara A, Tutucci C, Apice G, de Nigris F. Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells. Cancers. 2013; 5(2):404-417.
Infante, Teresa; Cesario, Elena; Gallo, Michele; Fazioli, Flavio; De Chiara, Annarosaria; Tutucci, Cristina; Apice, Gaetano; de Nigris, Filomena. 2013. "Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells." Cancers 5, no. 2: 404-417.